Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1990 Feb;99(2):389–395. doi: 10.1111/j.1476-5381.1990.tb14714.x

Enhancement by neuropeptide Y (NPY) of the dihydropyridine-sensitive component of the response to alpha 1-adrenoceptor stimulation in rat isolated mesenteric arterioles.

R Andriantsitohaina 1, J C Stoclet 1
PMCID: PMC1917373  PMID: 1970270

Abstract

1. The mechanism by which neuropeptide Y (NPY) potentiates the vasoconstriction induced by alpha 1-adrenoceptor agonists was investigated in 3rd generation mesenteric arterioles of the rat. 2. At a maximally active concentration, nitrendipine (10(-6) M) displaced to the right the concentration-response curves to noradrenaline (pD2 decreased from 6.2 +/- 0.06 to 5.7 +/- 0.03) and phenylephrine (pD2 decreased from 5.6 +/- 0.03 to 5.3 +/- 0.03). Diltiazem (10(-5) M) also shifted to the right the concentration-response curve to phenylephrine (pD2 decreased from 6.0 +/- 0.06 to 5.5 +/- 0.04). In addition, the maximal response to phenylephrine was significantly decreased in the presence of either nitrendipine or diltiazem. 3. In the absence of a calcium channel blocking agent, NPY (100 nM) produced a leftward shift of the concentration-response curves to noradrenaline (pD2 increased from 6.2 +/- 0.06 to 6.5 +/- 0.05) and phenylephrine (pD2 increased from 5.6 +/- 0.03 to 6.0 +/- 0.06 and from 6.0 +/- 0.06 to 6.3 +/- 0.11). In the presence of either nitrendipine (10(-6) M) or diltiazem (10(-5) M), NPY (100 nM) did not alter the concentration-response curves to either noradrenaline or phenylephrine. 4. NPY was added to arterioles brought to the same level of tension (40% of the maximal contraction) either by phenylephrine alone (1.5 x 10(-6) M) or by a higher concentration of phenylephrine (3 x 10(-6) M) followed by the addition of prazosin (1.3 x 10(-9) M; a concentration at which it partially blocks alpha 1-adrenoceptors).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
390

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abel P. W., Han C. Effects of neuropeptide Y on contraction, relaxation, and membrane potential of rabbit cerebral arteries. J Cardiovasc Pharmacol. 1989 Jan;13(1):52–63. [PubMed] [Google Scholar]
  2. Agnati L. F., Fuxe K., Benfenati F., Battistini N., Härfstrand A., Tatemoto K., Hökfelt T., Mutt V. Neuropeptide Y in vitro selectivity increases the number of alpha 2-adrenergic binding sites in membranes of the medulla oblongata of the rat. Acta Physiol Scand. 1983 Jul;118(3):293–295. doi: 10.1111/j.1748-1716.1983.tb07273.x. [DOI] [PubMed] [Google Scholar]
  3. Brayden J. E., Conway M. A. Neuropeptide Y and vasoactive intestinal polypeptide in cerebral arteries of the rat: relationships between innervation pattern and mechanical response. Regul Pept. 1988 Aug;22(3):253–265. doi: 10.1016/0167-0115(88)90038-9. [DOI] [PubMed] [Google Scholar]
  4. Cauvin C., Loutzenhiser R., Van Breemen C. Mechanisms of calcium antagonist-induced vasodilation. Annu Rev Pharmacol Toxicol. 1983;23:373–396. doi: 10.1146/annurev.pa.23.040183.002105. [DOI] [PubMed] [Google Scholar]
  5. Cauvin C., Malik S. Induction of Ca++ influx and intracellular Ca++ release in isolated rat aorta and mesenteric resistance vessels by norepinephrine activation of alpha-1 receptors. J Pharmacol Exp Ther. 1984 Aug;230(2):413–418. [PubMed] [Google Scholar]
  6. Dahlöf C., Dahlöf P., Lundberg J. M. Neuropeptide Y (NPY): enhancement of blood pressure increase upon alpha-adrenoceptor activation and direct pressor effects in pithed rats. Eur J Pharmacol. 1985 Feb 26;109(2):289–292. doi: 10.1016/0014-2999(85)90433-9. [DOI] [PubMed] [Google Scholar]
  7. Edvinsson L. Characterization of the contractile effect of neuropeptide Y in feline cerebral arteries. Acta Physiol Scand. 1985 Sep;125(1):33–41. doi: 10.1111/j.1748-1716.1985.tb07690.x. [DOI] [PubMed] [Google Scholar]
  8. Edvinsson L., Ekblad E., Håkanson R., Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol. 1984 Oct;83(2):519–525. doi: 10.1111/j.1476-5381.1984.tb16516.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edvinsson L., Emson P., McCulloch J., Tatemoto K., Uddman R. Neuropeptide Y: immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ. Acta Physiol Scand. 1984 Oct;122(2):155–163. doi: 10.1111/j.1748-1716.1984.tb07493.x. [DOI] [PubMed] [Google Scholar]
  10. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Håkanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept. 1984 Apr;8(3):225–235. doi: 10.1016/0167-0115(84)90064-8. [DOI] [PubMed] [Google Scholar]
  11. Exton J. H. Mechanisms of action of calcium-mobilizing agonists: some variations on a young theme. FASEB J. 1988 Aug;2(11):2670–2676. doi: 10.1096/fasebj.2.11.2456243. [DOI] [PubMed] [Google Scholar]
  12. Fredholm B. B., Jansen I., Edvinsson L. Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels. Acta Physiol Scand. 1985 Jul;124(3):467–469. doi: 10.1111/j.1748-1716.1985.tb07683.x. [DOI] [PubMed] [Google Scholar]
  13. Glover W. E. Increased sensitivity of rabbit ear artery to noradrenaline following perivascular nerve stimulation may be a response to neuropeptide Y released as cotransmitter. Clin Exp Pharmacol Physiol. 1985 May-Jun;12(3):227–230. doi: 10.1111/j.1440-1681.1985.tb02636.x. [DOI] [PubMed] [Google Scholar]
  14. Gray T. S., Morley J. E. Neuropeptide Y: anatomical distribution and possible function in mammalian nervous system. Life Sci. 1986 Feb 3;38(5):389–401. doi: 10.1016/0024-3205(86)90061-5. [DOI] [PubMed] [Google Scholar]
  15. Han C., Abel P. W., Minneman K. P. Alpha 1-adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle. Nature. 1987 Sep 24;329(6137):333–335. doi: 10.1038/329333a0. [DOI] [PubMed] [Google Scholar]
  16. Han C., Abel P. W. Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J Cardiovasc Pharmacol. 1987 Jun;9(6):675–681. doi: 10.1097/00005344-198706000-00006. [DOI] [PubMed] [Google Scholar]
  17. Hanko J. H., Törnebrandt K., Hardebo J. E., Kåhrström J., Nobin A., Owman C. Neuropeptide Y induces and modulates vasoconstriction in intracranial and peripheral vessels of animals and man. J Auton Pharmacol. 1986 Jun;6(2):117–124. doi: 10.1111/j.1474-8673.1986.tb00638.x. [DOI] [PubMed] [Google Scholar]
  18. Hassid A. Atriopeptin II decreases cytosolic free Ca in cultured vascular smooth muscle cells. Am J Physiol. 1986 Nov;251(5 Pt 1):C681–C686. doi: 10.1152/ajpcell.1986.251.5.C681. [DOI] [PubMed] [Google Scholar]
  19. Hinson J., Rauh C., Coupet J. Neuropeptide Y stimulates inositol phospholipid hydrolysis in rat brain miniprisms. Brain Res. 1988 Apr 19;446(2):379–382. doi: 10.1016/0006-8993(88)90898-0. [DOI] [PubMed] [Google Scholar]
  20. Häggblad J., Fredholm B. B. Adenosine and neuropeptide Y enhance alpha 1-adrenoceptor-induced accumulation of inositol phosphates and attenuate forskolin-induced accumulation of cyclic AMP in rat vas deferens. Neurosci Lett. 1987 Nov 23;82(2):211–216. doi: 10.1016/0304-3940(87)90132-7. [DOI] [PubMed] [Google Scholar]
  21. Juan H., Sametz W., Saria A., Pöch G. Eicosapentaenoic acid inhibits vasoconstrictor- and noradrenaline-potentiating effects of neuropeptide Y in the isolated rabbit ear. J Auton Nerv Syst. 1988 Apr;22(3):237–242. doi: 10.1016/0165-1838(88)90112-9. [DOI] [PubMed] [Google Scholar]
  22. Julou G., Freslon J. L. Effects of calcium entry blockers on Ca2+-induced contraction of depolarized and noradrenaline-exposed rat resistance vessels. Eur J Pharmacol. 1986 Oct 7;129(3):261–270. doi: 10.1016/0014-2999(86)90436-x. [DOI] [PubMed] [Google Scholar]
  23. Lundberg J. M., Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand. 1982 Dec;116(4):393–402. doi: 10.1111/j.1748-1716.1982.tb07157.x. [DOI] [PubMed] [Google Scholar]
  24. Lundberg J. M., Terenius L., Hökfelt T., Martling C. R., Tatemoto K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982 Dec;116(4):477–480. doi: 10.1111/j.1748-1716.1982.tb07171.x. [DOI] [PubMed] [Google Scholar]
  25. Morgan J. P., Morgan K. G. Alteration of cytoplasmic ionized calcium levels in smooth muscle by vasodilators in the ferret. J Physiol. 1984 Dec;357:539–551. doi: 10.1113/jphysiol.1984.sp015516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mulvany M. J., Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977 Jul;41(1):19–26. doi: 10.1161/01.res.41.1.19. [DOI] [PubMed] [Google Scholar]
  27. Mulvany M. J., Nilsson H., Flatman J. A. Role of membrane potential in the response of rat small mesenteric arteries to exogenous noradrenaline stimulation. J Physiol. 1982 Nov;332:363–373. doi: 10.1113/jphysiol.1982.sp014418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Neild T. O. Actions of neuropeptide Y on innervated and denervated rat tail arteries. J Physiol. 1987 May;386:19–30. doi: 10.1113/jphysiol.1987.sp016519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nichols A. J., Ruffolo R. R., Jr The relationship of alpha-adrenoceptor reserve and agonist intrinsic efficacy to calcium utilization in the vasculature. Trends Pharmacol Sci. 1988 Jul;9(7):236–241. doi: 10.1016/0165-6147(88)90152-6. [DOI] [PubMed] [Google Scholar]
  30. O'Donohue T. L., Chronwall B. M., Pruss R. M., Mezey E., Kiss J. Z., Eiden L. E., Massari V. J., Tessel R. E., Pickel V. M., DiMaggio D. A. Neuropeptide Y and peptide YY neuronal and endocrine systems. Peptides. 1985 Jul-Aug;6(4):755–768. doi: 10.1016/0196-9781(85)90180-9. [DOI] [PubMed] [Google Scholar]
  31. Paglin S., Takuwa Y., Kamm K. E., Stull J. T., Gavras H., Rasmussen H. Atrial natriuretic peptide inhibits the agonist-induced increase in extent of myosin light chain phosphorylation in aortic smooth muscle. J Biol Chem. 1988 Sep 15;263(26):13117–13120. [PubMed] [Google Scholar]
  32. Potter E. K. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther. 1988;37(2):251–273. doi: 10.1016/0163-7258(88)90028-9. [DOI] [PubMed] [Google Scholar]
  33. Reynolds E. E., Yokota S. Neuropeptide Y receptor-effector coupling mechanisms in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 1988 Mar 15;151(2):919–925. doi: 10.1016/s0006-291x(88)80369-3. [DOI] [PubMed] [Google Scholar]
  34. Saida K., van Breemen C. Mechanism of Ca++ antagonist-induced vasodilation. Intracellular actions. Circ Res. 1983 Feb;52(2):137–142. doi: 10.1161/01.res.52.2.137. [DOI] [PubMed] [Google Scholar]
  35. Seamon K. B., Daly J. W. Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1986;20:1–150. [PubMed] [Google Scholar]
  36. Suzuki Y., Shibuya M., Ikegaki I., Satoh S., Takayasu M., Asano T. Effects of neuropeptide Y on canine cerebral circulation. Eur J Pharmacol. 1988 Feb 9;146(2-3):271–277. doi: 10.1016/0014-2999(88)90302-0. [DOI] [PubMed] [Google Scholar]
  37. Tremblay J., Gerzer R., Hamet P. Cyclic GMP in cell function. Adv Second Messenger Phosphoprotein Res. 1988;22:319–383. [PubMed] [Google Scholar]
  38. Wahlestedt C., Edvinsson L., Ekblad E., Håkanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther. 1985 Sep;234(3):735–741. [PubMed] [Google Scholar]
  39. Wahlestedt C., Yanaihara N., Håkanson R. Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept. 1986 Feb;13(3-4):307–318. doi: 10.1016/0167-0115(86)90048-0. [DOI] [PubMed] [Google Scholar]
  40. Zukowska-Grojec Z., Haass M., Bayorh M. A. Neuropeptide Y and peptide YY mediate nonadrenergic vasoconstriction and modulate sympathetic responses in rats. Regul Pept. 1986 Sep;15(2):99–110. doi: 10.1016/0167-0115(86)90080-7. [DOI] [PubMed] [Google Scholar]
  41. Zukowska-Grojec Z., Marks E. S., Haass M. Neuropeptide Y is a potent vasoconstrictor and a cardiodepressant in rat. Am J Physiol. 1987 Nov;253(5 Pt 2):H1234–H1239. doi: 10.1152/ajpheart.1987.253.5.H1234. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES